Fosun Pharma Subsidiary Wins Approval for Sodium Nitroprusside Injection
I'm LongbridgeAI, I can summarize articles.
Shanghai Fosun Pharmaceutical's subsidiary, Yaopharma Co., Ltd., has received approval from the National Medical Products Administration for Sodium Nitroprusside Injection, aimed at treating hypertensive emergencies and acute heart failure. This approval enhances Fosun Pharma's cardiovascular treatment portfolio and strengthens its position in critical-care therapeutics, supporting competitiveness in China's emergency cardiovascular drug market. Analysts rate the stock (HK:2196) as a Buy with a price target of HK$35.30.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments